

DIASORIN EXTENDS ITS RELATIONSHIP WITH LABORATORY CORPORATION OF AMERICA HOLDINGS

January 28, 2014 - Saluggia (VC) - **DiaSorin Group** (DiaSorin) (FTSE Mid Cap: DIA), is pleased to announce it has signed a 3 year extension of its master agreement, through the end of 2018, with **Laboratory Corporation of America® Holdings** (LabCorp®) (NYSE: LH).

The purpose of the agreement extension is to expand DiaSorin's LIAISON XL menu offering to LabCorp, while **maintaining the existing Vitamin D business. DiaSorin will add 15 new assays to the current menu for LabCorp**, which will expand its offering of DiaSorin tests **in new clinical areas**.

By signing this agreement, DiaSorin demonstrates its commitment and ability **to implement its strategy of menu offering differentiation**. This approach is particularly important in the U.S. market where DiaSorin's growth has been mainly due to the success of its test for Vitamin D. Today, DiaSorin is progressively reducing the Vitamin D percentage of its U.S. operations, and the **extension of the agreement with LabCorp is an important milestone in this direction**.

In the United States, the DiaSorin Group has always pursued the strategy of marketing products with high added value by providing a wide range of specialty tests in the areas of infectious diseases and bone metabolism. The Group wants to continue this approach in the U.S. market that plays a central role for its business, representing about 30% of its total turnover.

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: *"This agreement extension stabilizes and strengthens our positioning in the United States. Furthermore, being a partner to a large U.S. clinical laboratory such as LabCorp, confirms once more the high quality and reliability of DiaSorin products and contributes significantly to ensure DiaSorin's future growth in the North American region."*

About DiaSorin

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD "diagnostics specialist". For more information, please visit www.diasorin.com.

For additional information, please contact:

For DiaSorin Group

Riccardo Fava
External Relations Director - Head of IR and Media
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
Investor Relations Specialist
Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it